Inebilizumab Beneficial Across Genotypes in NMOSD
Inebilizumab is effective for neuromyelitis optica spectrum disorder, even among patients who are genetically at risk for reduced response to anti-CD20 therapies, new research suggests.
South Korea United States Marcelo Matiello Neuromyelitis Optica Bruce Cree Consortium Of Multiple Sclerosis Centers
Source: medscape.com